In spite of its modest performance in clinical trials, Benlysta may offer effective relief against lupus. But physicians are still working to identify the right patients. Michael Eisenstein reports.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Immune checkpoint receptors in regulating immune reactivity in rheumatic disease
Arthritis Research & Therapy Open Access 29 October 2014
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Stohl, W. & Hilbert, D.M. Nat. Biotechnol. 30, 69–77 (2012).
Petri, M. et al. Arthritis Rheum. 58, 2453–2459 (2008).
Anonymous. Guidance for Industry: Systemic Lupus Erythematosus—Developing Medical Products for Treatment (FDA, 2010). <http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm072063.pdf>
Wallace, D.J. et al. Arthritis Rheum. 61, 1168–1178 (2009).
Navarra, S.V. et al. Lancet 377, 721–731 (2011).
Furie, R. et al. Arthritis Rheum. 62, S606 (2010).
Mount, G.R. & Gilliland, W.R. Clin. Pharmacol. Ther. 83, 167–171 (2008).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Eisenstein, M. Approval on a knife edge. Nat Biotechnol 30, 26–29 (2012). https://doi.org/10.1038/nbt.2084
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt.2084
This article is cited by
-
Lupus in crisis: as failures pile up, clinicians call for new tools
Nature Biotechnology (2019)
-
Immune checkpoint receptors in regulating immune reactivity in rheumatic disease
Arthritis Research & Therapy (2014)